Lineage Cell Therapeutics: Broadwood buys 1M shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Broadwood Partners, L.P. purchased 1,000,000 Lineage Cell Therapeutics common shares at $0.7707 per share on November 17, 2026. The shares are directly owned by Broadwood Partners. Broadwood Capital, Inc., its general partner, and Neal C. Bradsher, Broadwood Capital’s president, may be deemed beneficial owners; each disclaims beneficial ownership except to the extent of a pecuniary interest. No Rule 10b5-1 plan is reported.
The report lists directly held Common Warrants exercisable for 7,894,737 common shares at $0.91 per share. They are currently exercisable and expire on the earlier of May 21, 2028, or the 90th day following public disclosure of intent to advance OpRegen (RG6501) into a multi-center phase 2 or 3 clinical trial with a control or comparator arm. If that disclosure occurs before May 21, 2025, the stated expiration is the 90th day following May 21, 2025.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Shares F1 | 1,000,000 | $0.7707 | $771K |
| Purchase | Common Shares F1 | 0 | $0.00 | $0.00 |
| Holding | Common Warrant F3, F4, F1 | -- | -- | -- |
| Holding | Common Warrant F3, F4, F1 | -- | -- | -- |
| Holding | Common Shares F2 | -- | -- | -- |
Footnotes (4)
- F1. The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners and Neal C. Bradsher as President of Broadwood Capital, Inc. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- F2. These securities are owned by Neal C. Bradsher in his personal capacity.
- F3. These common share purchase warrants (the "Common Warrants") are currently exercisable.
- F4. The Common Warrants will expire on the earlier of (a) May 21, 2028 and (b) the 90th day following the date of the public disclosure of the intent to advance OpRegen (also known as RG6501) into a multi-center phase 2 or 3 clinical trial which includes a control or comparator arm, or if the date of such public disclosure occurs prior to May 21, 2025, then the 90th day following May 21, 2025.
Key Figures
Key Terms
Common Warrants technical
beneficially owned regulatory
pecuniary interest financial
General Partner technical
multi-center phase 2 or 3 clinical trial medical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When do the reported LCTX warrants expire?
AI-generated analysis. How Rhea-AI works. Not financial advice.